ImmuneOnco’s IMM40H Receives NMPA Clinical Trial Approval for CD70 Antibody
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that it has received clinical trial approval from the...
Cancer
InnoCare Pharma Files for STAR Market IPO to Raise RMB 4B for Drug R&D
China-based InnoCare Pharma (HKG: 9969) has filed for an initial public offering (IPO) on the...
Sirnaomics’ STP705 Achieves 100% Complete Remission in Basal Cell Carcinoma Study
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced positive results from a Phase II...
Henlius Biotech’s PD-1 Inhibitor Serplulimab Secures NMPA Review for Esophageal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...
Junshi Biosciences’ TAB009/JS009 and JS110 Advance in Cancer Trials
Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...
Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study
Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...
Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases
Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III...
Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial
Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...
Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou...
Ranok Therapeutics Doses First Patient in RNK05047 Study for BRD4-Targeted Cancers
Ranok Therapeutics Co., Ltd, a Hangzhou-based biotech firm, announced that the first patient has been...
Mabwell Bioscience Receives NMPA Approval for 6MW3511 Clinical Trial in Solid Tumors
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the National Medical Products Administration...
Bio-Thera Solutions Receives NMPA Approval for BAT8008 Clinical Trial in Solid Tumors
Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biotech firm, has received approval from the National Medical...
BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA)...
BIOPSEE Series A+ Financing Confocal Microendoscope
BIOPSEE, a Hubei-based microendoscope specialist, has raised tens of millions of renminbi in a Series...
Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC
Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration...
InnoCare Pharma’s 2022 Interim Report Shows Strong Revenue Growth Driven by Orelabrutinib Sales
China-based InnoCare Pharma (HKG: 9969) announced its 2022 interim financial results, reporting total revenues of...
Allist Pharmaceuticals Receives NMPA Approval for Furmonertinib in Exon 20 Insertion NSCLC
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that the National Medical Products Administration (NMPA) has...
Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China
Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...
mProbe Raises Funds in Series B1 Round Led by AstraZeneca and CICC
Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an...
Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...